Open-Label Risperidone for Asperger's Disorder: Negative Symptom Spectrum Response
J Clin Psychiatry 2005;66(12):1592-1597
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: Asperger's disorder consists
of negative symptoms similar to those seen in schizophrenia, autism, schizoid personality
disorder, and schizotypal personality disorder. We investigated whether risperidone, which is
effective in treating the negative symptoms of
schizophrenia, would improve such symptoms
observed in Asperger's disorder in a prospective,
Method: Thirteen male patients aged 6 to
18 years who were diagnosed with Asperger's disorder by DSM-IV criteria were enrolled in a
12-week, prospective, open-label pilot study from March 13, 2002 to August 11, 2003. All
subjects were started on risperidone 0.25 mg twice
per day. Doses were increased based on clinical
indication and tolerability. The primary efficacy
variable was the Scale for the Assessment of Negative Symptoms (SANS). Each subject's
baseline score served as his control. Secondary
efficacy measures included the Positive and Negative
Syndrome Scale, Brief Psychiatric Rating Scale, Montgomery-Asberg Depression Rating
Scale, Global Assessment Scale, and a modified Asperger Syndrome Diagnostic Scale.
Results: We found a statistically
significant improvement from baseline for
last-observation-carried-forward (LOCF) analyses as well as
for analyses of 12-week completers (N = 9) in our primary outcome measure, SANS
scores (F = 13.41, p < .0001 for 12-week
completers; F = 9.64, p < .0001 for LOCF). We also found
statistically significant improvement in all
secondary efficacy measurements (F values range, 8.41 to 15.73, p values range, < .0001 for LOCF).
Conclusions: Subjects' symptoms
significantly improved after risperidone. The
open-label nature of this small pilot study suggests
caution in interpreting these data, but the results
suggest that placebo-controlled trials should follow.